



ASX ANNOUNCEMENT

12 May 2021

New Patent Granted for Blood Pressure Measurement by US Patent Office

Highlights:

- CardieX subsidiary ATCOR has been granted US Patent 11,006,842 by the US Patent & Trademark Office (USPTO) further enhancing the Company's intellectual property surrounding blood pressure measurement.
- Patent provides for a new method of estimating brachial blood pressure from cuff-based blood pressure devices and wearable sensor technology.
- Patent is in force until 2038.

CardieX Limited (ASX: CDX) (CardieX, the Company) is pleased to announce that CardieX subsidiary ATCOR, has been granted a new patent by the USPTO in relation to intellectual property (IP) surrounding the Company's patented SphygmoCor® technology.

US Patent No 11,006,842, titled "*Non-Invasive Brachial Blood Pressure Measurement*" has been granted specifically to protect the Company's IP in relation to the measurement of central blood pressure waveforms using a brachial blood pressure cuff.

The granting of this patent further builds on the Company's existing 13 patents surrounding the measurement of cardiovascular health parameters using both traditional brachial cuff devices as well as sensor-based wearable technologies.

In May 2020, ATCOR also lodged an additional new patent application for what is believed to be a world-first wearable sensor technology method and system using a PPG sensor - which the Company is incorporating in upcoming product releases.

The patent is in force until 2038.

Approved for release by the Board of Directors.

For more information please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com

About CardieX

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. CardieX is listed on the Australian Stock Exchange (ASX:CDX).